Byoong Yong Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Byoong Yong Choi has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Han Joo Baek
Department of Internal Medicine, Pyeongchang Health Center and County Hospital, Pyeongchang, Korea
5 shared publications - Eun Bong Lee
Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
4 shared publications - Kichul Shin
Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea
4 shared publications - Seung-Jae Hong
Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea
4 shared publications - Yoon-Kyoung Sung
Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea
3 shared publications - Ji Hyoun Kim
Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea
2 shared publications
Latest Publications
- Open Access
- 12 December 2023
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 31 (1) , 59-61
Insights from the COVID-19 pandemic: underscoring the paramount value of patient education and counseling for rheumatic diseases
Byoong Yong Choi, M.D., Myeung-Su Lee, M.D., Ph.D., Geun Tae Kim, M.D., Ph.D., Seung-Jae Hong, M.D., Ph.D., Eun Bong Lee, M.D., Ph.D., Han Joo Baek, M.D., Ph.D. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2023.0068
- 12 December 2023
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 31 (1) , 59-61
Open AccessInsights from the COVID-19 pandemic: underscoring the paramount value of patient education and counseling for rheumatic diseases
Byoong Yong Choi, M.D., Myeung-Su Lee, M.D., Ph.D., Geun Tae Kim, M.D., Ph.D., Seung-Jae Hong, M.D., Ph.D., Eun Bong Lee, M.D., Ph.D., Han Joo Baek, M.D., Ph.D. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2023.0068
- Open Access
- 22 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-7
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
Achieving target serum uric acid (SUA) levels is important in gout management. Guidelines recommend lowering SUA levels to < 6 mg/dL; however, many patients fail to reach this target, even with uric acid-lowering therapy (ULT). This study investigated clinical characteristics of target SUA achievers among Korean patients with gout. This study used data from the ULTRA registry, a nationwide inception cohort established in September 2021 that enrolls patients with gout who initiate ULT. Demographic, clinical, and laboratory data were collected at baseline; the 6-month follow-up. Patients were divided into two groups: target achievers (SUA level < 6 mg/dL at 6 months) and non-achievers. The mean participant (N = 117) age was 56.1 years, and 88.0% were male. At 6 months, 83 patients (70.9%) reached target SUA levels. Target achievers had better drug adherence (≥ 80%) to ULT (97.6% vs. 76.5%; p < 0.01) than non-achievers. Target non-achievers had a higher percentage of a family history of gout (32.4% vs. 10.8%; p < 0.01) and less antihypertensive agent use (38.2% vs. 59.0%; p = 0.03) than target achievers. Multivariate regression analysis revealed that good adherence to ULT, the absence of a family history of gout, and antihypertensive agent use were key factors associated with achieving target SUA levels at 6 months.
- 22 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-7
Open AccessFactors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
Achieving target serum uric acid (SUA) levels is important in gout management. Guidelines recommend lowering SUA levels to < 6 mg/dL; however, many patients fail to reach this target, even with uric acid-lowering therapy (ULT). This study investigated clinical characteristics of target SUA achievers among Korean patients with gout. This study used data from the ULTRA registry, a nationwide inception cohort established in September 2021 that enrolls patients with gout who initiate ULT. Demographic, clinical, and laboratory data were collected at baseline; the 6-month follow-up. Patients were divided into two groups: target achievers (SUA level < 6 mg/dL at 6 months) and non-achievers. The mean participant (N = 117) age was 56.1 years, and 88.0% were male. At 6 months, 83 patients (70.9%) reached target SUA levels. Target achievers had better drug adherence (≥ 80%) to ULT (97.6% vs. 76.5%; p < 0.01) than non-achievers. Target non-achievers had a higher percentage of a family history of gout (32.4% vs. 10.8%; p < 0.01) and less antihypertensive agent use (38.2% vs. 59.0%; p = 0.03) than target achievers. Multivariate regression analysis revealed that good adherence to ULT, the absence of a family history of gout, and antihypertensive agent use were key factors associated with achieving target SUA levels at 6 months.
- Open Access
- 20 July 2022
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 29 (4) , 243-253
Isolated Tuberculous Myositis: A Systematic Review and Multicenter Cases
Ji Hyoun Kim, M.D., Jeong Seok Lee, M.D., Ph.D., Byoong Yong Choi, M.D., Yun-Hong Cheon, M.D., Su-Jin Yoo, M.D., Ph.D., Ji Hyeon Ju, M.D., Ph.D., Kichul Shin, M.D., Ph.D., Eu Suk Kim, M.D., Ph.D., Han Joo Baek, M.D., Ph.D., Won Park, M.D., Ph.D., Yeong Wook Song, M.D., Ph.D., Woi-Hyun Hong, Ph.D., Yun Jong Lee, M.D., Ph.D.. J Rheum Dis 2022;29:243-53. https://doi.org/10.4078/jrd.22.0014
- 20 July 2022
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 29 (4) , 243-253
Open AccessIsolated Tuberculous Myositis: A Systematic Review and Multicenter Cases
Ji Hyoun Kim, M.D., Jeong Seok Lee, M.D., Ph.D., Byoong Yong Choi, M.D., Yun-Hong Cheon, M.D., Su-Jin Yoo, M.D., Ph.D., Ji Hyeon Ju, M.D., Ph.D., Kichul Shin, M.D., Ph.D., Eu Suk Kim, M.D., Ph.D., Han Joo Baek, M.D., Ph.D., Won Park, M.D., Ph.D., Yeong Wook Song, M.D., Ph.D., Woi-Hyun Hong, Ph.D., Yun Jong Lee, M.D., Ph.D.. J Rheum Dis 2022;29:243-53. https://doi.org/10.4078/jrd.22.0014
- Open Access
- 1 April 2022
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 29 (2) , 108-115
Differential Diagnosis of Inflammatory Arthropathy Accompanying Active Tuberculosis Infection
Youjin Jung, M.D., Byoong Yong Choi, M.D.. J Rheum Dis 2022;29:108-15. https://doi.org/10.4078/jrd.2022.29.2.108
- 1 April 2022
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 29 (2) , 108-115
Open AccessDifferential Diagnosis of Inflammatory Arthropathy Accompanying Active Tuberculosis Infection
Youjin Jung, M.D., Byoong Yong Choi, M.D.. J Rheum Dis 2022;29:108-15. https://doi.org/10.4078/jrd.2022.29.2.108
- Open Access
- 27 September 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (38) , e270
Erratum: Correction of Authors' Name Spelling in the Article “COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology”
Park JK, et al. J Korean Med Sci. 2021 Sep;36(38):e270. https://doi.org/10.3346/jkms.2021.36.e270
- 27 September 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (38) , e270
Open AccessErratum: Correction of Authors' Name Spelling in the Article “COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology”
Park JK, et al. J Korean Med Sci. 2021 Sep;36(38):e270. https://doi.org/10.3346/jkms.2021.36.e270
- Open Access
- 29 June 2021
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 19 (1) , 1-7
Assessing the performance of a method for case-mix adjustment in the Korean Diagnosis-Related Groups (KDRG) system and its policy implications
Background: To evaluate the performance of the patient clinical complexity level (PCCL) mechanism, which is the patient-level complexity adjustment factor within the Korean Diagnosis-Related Groups (KDRG) patient classification system, in explaining the variation in resource consumption within age adjacent diagnosis-related groups (AADRGs). Methods: We used the inpatient claims data from a public hospital in Korea from 1 January 2017 to 30 June 2019, with 18 846 claims and 138 AADRGs. The differences in the total average payment between the four PCCL levels for each AADRG was tested using ANOVA and Duncan’s post hoc test. The three patterns of differences with R-squared were as follows: the PCCL reflected the complexity well (valid); the average payment for PCCL 2, 3, and 4 was greater than PCCL 0 (partially valid); the PCCL did not reflect the complexity (not valid). Results: There were 9 (6.52%), 26 (18.84%), and 103 (74.64%) ADRGs included in the valid, partially valid, and not valid categories, respectively. The average R-squared values were 32.18, 40.81, and 35.41%, respectively, with an average R-squared for all patterns of 36.21%. Conclusions: Adjustment using the PCCL in the KDRG classification system exhibited low performance in explaining the variation in resource consumption within AADRGs. As the KDRG classification system is used for reimbursement under the new DRG-based prospective payment system (PPS) pilot project, with plans for expansion, there should be an overall review of the validity of the complexity and rationality of using the KDRG classification system.
- 29 June 2021
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 19 (1) , 1-7
Open AccessAssessing the performance of a method for case-mix adjustment in the Korean Diagnosis-Related Groups (KDRG) system and its policy implications
Background: To evaluate the performance of the patient clinical complexity level (PCCL) mechanism, which is the patient-level complexity adjustment factor within the Korean Diagnosis-Related Groups (KDRG) patient classification system, in explaining the variation in resource consumption within age adjacent diagnosis-related groups (AADRGs). Methods: We used the inpatient claims data from a public hospital in Korea from 1 January 2017 to 30 June 2019, with 18 846 claims and 138 AADRGs. The differences in the total average payment between the four PCCL levels for each AADRG was tested using ANOVA and Duncan’s post hoc test. The three patterns of differences with R-squared were as follows: the PCCL reflected the complexity well (valid); the average payment for PCCL 2, 3, and 4 was greater than PCCL 0 (partially valid); the PCCL did not reflect the complexity (not valid). Results: There were 9 (6.52%), 26 (18.84%), and 103 (74.64%) ADRGs included in the valid, partially valid, and not valid categories, respectively. The average R-squared values were 32.18, 40.81, and 35.41%, respectively, with an average R-squared for all patterns of 36.21%. Conclusions: Adjustment using the PCCL in the KDRG classification system exhibited low performance in explaining the variation in resource consumption within AADRGs. As the KDRG classification system is used for reimbursement under the new DRG-based prospective payment system (PPS) pilot project, with plans for expansion, there should be an overall review of the validity of the complexity and rationality of using the KDRG classification system.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (17) , e109
Quality Indicators for Evaluating the Health Care of Patients with Rheumatoid Arthritis: a Korean Expert Consensus
Seo MR, et al. J Korean Med Sci. 2021 Apr;36(17):e109. https://doi.org/10.3346/jkms.2021.36.e109
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (17) , e109
Open AccessQuality Indicators for Evaluating the Health Care of Patients with Rheumatoid Arthritis: a Korean Expert Consensus
Seo MR, et al. J Korean Med Sci. 2021 Apr;36(17):e109. https://doi.org/10.3346/jkms.2021.36.e109
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (12) , e95
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
Park JK, et al. J Korean Med Sci. 2021 Mar;36(12):e95. https://doi.org/10.3346/jkms.2021.36.e95
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (12) , e95
Open AccessCOVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
Park JK, et al. J Korean Med Sci. 2021 Mar;36(12):e95. https://doi.org/10.3346/jkms.2021.36.e95
- Open Access
- 1 January 2017
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 24 (1) , 48-54
Four Cases of Polyarteritis Nodosa Presenting Initially as Pain and Pitting Edema in Both Lower Extremities
Lee HS, et al. J Rheum Dis. 2017 Feb;24(1):48-54. https://doi.org/10.4078/jrd.2017.24.1.48
- 1 January 2017
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 24 (1) , 48-54
Open AccessFour Cases of Polyarteritis Nodosa Presenting Initially as Pain and Pitting Edema in Both Lower Extremities
Lee HS, et al. J Rheum Dis. 2017 Feb;24(1):48-54. https://doi.org/10.4078/jrd.2017.24.1.48
- Open Access
- 1 January 2016
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 23 (1) , 71-75
Successful Infliximab Therapy in a Patient with Refractory Takayasu's Arteritis
An J, et al. J Rheum Dis. 2016 Feb;23(1):71-75. http://dx.doi.org/10.4078/jrd.2016.23.1.71
- 1 January 2016
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 23 (1) , 71-75
Open AccessSuccessful Infliximab Therapy in a Patient with Refractory Takayasu's Arteritis
An J, et al. J Rheum Dis. 2016 Feb;23(1):71-75. http://dx.doi.org/10.4078/jrd.2016.23.1.71